UW Comprehensive Cancer Center Support

描述（由申请人提供）：威斯康星大学麦迪逊分校在基础、转化和临床癌症研究方面具有悠久而丰富的历史。它的历史反映了两个NCI指定的癌症研究中心的发展，这两个中心是由Harold Rusch博士在威斯康星大学麦迪逊分校创建的。麦卡德尔癌症研究实验室成立于1940年，威斯康星大学综合癌症中心于1973年获得NCI资助，成为首批综合癌症中心之一。今天，威斯康星大学综合癌症中心由来自威斯康星大学麦迪逊分校52个系和9个学院的253名成员组成。组织结构将这个多样化的研究人员社区聚集在一起，以七个科学研究项目和十五个疾病导向工作组为中心。这些成员总共获得了1.05亿美元用于癌症相关研究的直接费用资助，其中8900万美元是同行评审的。2800万美元来自NCI， 5100万美元来自其他NIH研究所，1000万美元来自其他同行评议来源。

DESCRIPTION (provided by applicant): The University of Wisconsin Madison has a long and rich history as an international leader in basic, translational and clinical cancer research. Its history reflects the development of two NCI designated cancer research centers founded by Dr. Harold Rusch on the campus of UW Madison. The McArdle Laboratory for Cancer Research was founded in 1940 and the University of Wisconsin Comprehensive Cancer Center was awarded NCI funding as one of the first comprehensive cancer centers in 1973. Today the University of Wisconsin Comprehensive Cancer Center is comprised of 253 members from 52 departments and 9 schools of the University of Wisconsin Madison. The organizational structure that brings together this diverse community of investigators is centered around seven scientific research programs and fifteen Disease Oriented Working Groups. Together the members receive $105M in direct cost funding for cancer related research, $89M is peer-reviewed. $28M is from NCI, $51M from other NIH Institutes, and $10M from other peer-reviewed sources. The three highest goals of the UWCCC, now and for the future, are: 1) to conduct the highest quality research into the origins and control of cancer; 2) to translate these research findings to evaluation in the clinic through well designed clinical trials with corresponding biologic endpoints whenever possible; and 3) to provide the best care possible to all cancer patients by carefully integrating high quality cutting edge care with clinical research in a compassionate and individualized manner. To address these goals during the next grant period, UWCCC priorities for future development will be: * Strengthening of programmatic cancer focused intra- and transdisciplinary basic and clinical research capabilities especially in Aging and Cancer and in Immunology * Focus research on health disparities and the delivery of outstanding cancer care to all populations * Enhancement of research infrastructure by further development of shared resources * Completion of clinical and research facility remodeling and expansions